Want to see UPB full AI Analyst Report?

Upstream Bio, Inc. (UPB) Price & Analysis

270 Followers

UPB Stock Chart & Stats

$7.13

>-$0.01(-0.16%)

At close: Jul 27 4:00 PM EDT

$7.13

>-$0.01(-0.16%)

Day’s Range― - ―

52-Week Range$4.98 - $33.68

Previous Close$6.3

Volume459.48K

Average Volume (3M)571.65K

Market Cap

$288.64M

Enterprise Value$117.26

Total Cash (Recent Filing)$261.31M

Total Debt (Recent Filing)$954.00K

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Nov 05, 2026

EPS Estimate

-0.73

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.90

Shares Outstanding54,771,040

10 Day Avg. Volume570,505

30 Day Avg. Volume571,646

Financial Highlights & Ratios

PEG Ratio-0.13

Price to Book (P/B)4.30

Price to Sales (P/S)512.30

P/FCF Ratio-10.97

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$22.25

Price Target Upside212.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-2.87

Revenue Forecast (FY)$2.71M

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low debt reduces financial risk and limits the burden of interest or refinancing obligations while the company advances its clinical programs. Positive equity provides a stronger capital base than a highly leveraged structure, preserving flexibility if operating performance improves or additional funding is required.

Phase 3 Development VisibilityDefined Phase 3 plans create a clearer development path for the lead candidate and establish upcoming clinical milestones beyond the current research stage. Starting pivotal studies in two respiratory indications could improve the program’s strategic value if efficacy and safety are confirmed.

Focused Respiratory PipelineA focused biologics strategy addresses severe respiratory diseases driven by immune inflammation, giving the company a clear therapeutic area rather than a fragmented development approach. Concentrating resources on serious conditions may support deeper clinical expertise and program continuity.

Bears Say

Minimal Declining RevenueThe very small and recently declining revenue base provides little operating support relative to the company’s research and development commitments. Until clinical programs generate meaningful commercial revenue, the business has limited demonstrated ability to fund its activities through operations.

Large Net LossesDeepening losses show that current operating expenses substantially exceed revenue, leaving profitability dependent on successful clinical advancement and eventual commercialization. Persistently negative earnings can also erode the equity base over time if improved results or external funding do not offset spending.

Heavy Cash BurnCash burn is translating reported losses into substantial real cash usage, rather than reflecting mainly non-cash accounting charges. Continued outflows increase reliance on external funding until spending moderates or revenue scales, making capital access an important constraint on development plans.

Upstream Bio, Inc. News

Upstream Bio presents results from VALIANT trial at ERS Congress

Upstream Bio (UPB) presented results from the Phase 2 VALIANT clinical trial evaluating the safety and efficacy of...

24d ago

UPB

Upstream Pharma Earns Buy Rating as Verekitug’s Differentiated TSLP Strategy Advances Into Pivotal Phase III for Severe Asthma and CRSwNP

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on...

24d ago

UPB

FDA-Supported Streamlined Phase 3 Program and Strong Long-Term Asthma Upside Underpin Buy Rating with Unchanged $19 Price Target

Kate Dellorusso, an analyst from LifeSci Capital, maintained the Buy rating on Upstream Bio, Inc.. The associated price...

1M ago

UPB

Upstream Bio unveils Phase 3 plans for Verekitug in asthma, nasal polyps

Upstream Bio (UPB) announced its pivotal Phase 3 development plans for Verekitug in severe asthma and chronic rhinosinusitis...

1M ago

UPB

Upstream Bio Outlines Phase 3 Plans for Verekitug

Upstream Bio, Inc. ( ($UPB) ) just unveiled an announcement. On September 1, 2026, Upstream Bio announced detailed...

1M ago

UPB

Upstream Bio price target lowered to $25 from $43 at Truist

Truist analyst Danielle Brill lowered the firm’s price target on Upstream Bio (UPB) to $25 from $43 and...

2M ago

UPB

Upstream Bio price target raised to $9 from $8 at JPMorgan

JPMorgan raised the firm’s price target on Upstream Bio (UPB) to $9 from $8 and keeps a Neutral...

2M ago

UPB

Matt Phipps Initiates Buy on Upstream Bio, Citing Favorable FDA Progress and Best-in-Class Potential for Verekitug

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating today....

2M ago

UPB

Upstream Bio price target lowered to $25 from $43 at Truist

Truist lowered the firm’s price target on Upstream Bio (UPB) to $25 from $43 and keeps a Buy...

2M ago

UPB

Upstream Bio reports Q2 revenue $773,000, consensus $377,250

“We continued to make progress toward the initiation of our Phase 3 trials in severe asthma and CRSwNP...

2M ago

UPB

UPB Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Upstream Bio, Inc. (UPB) is scheduled to report 2nd quarter earnings on 08/12/2026. Regarding Q2 estimates, Wall Street...

2M ago

UPB

Upstream Bio management to meet with Piper Sandler

Meeting to be held in New York on June 23 hosted by Piper Sandler. Published first on TheFly...

4M ago

UPB

Upstream Bio presents new responder analyses from VIBRANT trial of verekitug

Upstream Bio (UPB) presented new responder analyses from the Phase 2 VIBRANT trial of verekitug in participants with...

4M ago

UPB

Upstream Bio downgraded to Neutral from Overweight at JPMorgan

JPMorgan downgraded Upstream Bio (UPB) to Neutral from Overweight with a price target of $8, down from $35....

4M ago

UPB

UPB FAQ

What was Upstream Bio, Inc.’s price range in the past 12 months?

Upstream Bio, Inc. lowest stock price was $4.98 and its highest was $33.68 in the past 12 months.

What is Upstream Bio, Inc.’s market cap?

Upstream Bio, Inc.’s market cap is $288.64M.

When is Upstream Bio, Inc.’s upcoming earnings report date?

Upstream Bio, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 34 days.

How were Upstream Bio, Inc.’s earnings last quarter?

Upstream Bio, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.744 by $0.014.

Is Upstream Bio, Inc. overvalued?

According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Upstream Bio, Inc. pay dividends?

Upstream Bio, Inc. does not currently pay dividends.

What is Upstream Bio, Inc.’s EPS estimate?

Upstream Bio, Inc.’s EPS estimate is -0.73.

How many shares outstanding does Upstream Bio, Inc. have?

Upstream Bio, Inc. has 54,771,040 shares outstanding.

What happened to Upstream Bio, Inc.’s price movement after its last earnings report?

Upstream Bio, Inc. reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.744. Following the earnings report the stock price went down -4.704%.

Which hedge fund is a major shareholder of Upstream Bio, Inc.?

Currently, no hedge funds are holding shares in UPB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Upstream Bio, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-33.14%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Upstream Bio, Inc.

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.

Upstream Bio, Inc. (UPB) Earnings & Revenues

Historic Earnings Reports

UPB Stock 12 Month Forecast

Average Price Target

$22.25

▲(212.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","37":"$37","12.25":"$12.25","20.5":"$20.5","28.75":"$28.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,12.25,20.5,28.75,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.04,7.421538461538462,9.803076923076922,12.184615384615384,14.566153846153846,16.947692307692307,19.32923076923077,21.71076923076923,24.092307692307692,26.473846153846154,28.855384615384615,31.236923076923077,33.61846153846154,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.04,6.363846153846154,7.687692307692307,9.01153846153846,10.335384615384616,11.65923076923077,12.983076923076922,14.306923076923077,15.630769230769232,16.954615384615384,18.27846153846154,19.602307692307694,20.926153846153845,{"y":22.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.04,5.344615384615385,5.649230769230769,5.953846153846154,6.258461538461539,6.563076923076923,6.867692307692308,7.172307692307692,7.476923076923077,7.781538461538462,8.086153846153845,8.39076923076923,8.695384615384615,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.63,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.94,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.08,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.31,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.55,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.04,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >